Trial Profile

A Phase II Randomized Trial of Camrelizumab With Stereotactic Body Radiotherapy Versus Camrelizumab Alone in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Mar 2025 Primary endpoint has not been met (ORR of unirradiated lesions) , according to Results published in the International Journal of Radiation Oncology, Biology, Physics
15 Mar 2025 According to results published in the International Journal of Radiation Oncology, Biology, Physics, trial accrual was completed on 16 Aug 2023.
15 Mar 2025 Results (cutoff date: 16 March 2024) published in the International Journal of Radiation Oncology, Biology, Physics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com